Cigna Corp (CI)

Currency in USD
282.49
+7.24(+2.63%)
Closed·
282.47-0.02(-0.01%)
·

CI Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
7.78 / 7.59
Revenue / Forecast
71.7B / 70.18B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2026--/7.52--/72.63B----Free Sign Up
06/20267.78/7.5971.70B/70.18B+2.5%+2.17%Free Sign Up
03/20267.79/7.6168.52B/66.20B+2.37%+3.5%Free Sign Up
12/20258.08/7.8872.47B/70.31B+2.54%+3.07%Free Sign Up
09/20257.83/7.6469.70B/67.61B+2.49%+3.09%Free Sign Up
06/20257.20/7.1667.20B/62.66B+0.56%+7.25%Free Sign Up
03/20256.74/6.3565.50B/60.38B+6.14%+8.48%Free Sign Up
12/20246.64/7.7965.65B/63.16B-14.76%+3.94%Free Sign Up
09/20247.51/7.2363.70B/59.64B+3.87%+6.81%Free Sign Up
06/20246.72/6.4360.52B/58.30B+4.51%+3.81%Free Sign Up

All numbers in USD

Cigna Corp Earnings Call Summary for Q2/2026

  • Cigna Q2 adjusted EPS of $7.78 beat estimates by 2.5%; revenue of $71.7B topped forecasts by 2.17%, yet shares fell 4.1% on investor caution.
  • Full-year 2026 adjusted EPS guidance raised to at least $30.45; Evernorth and Cigna Healthcare pre-tax earnings targets reaffirmed at $6.9B and $4.55B.
  • Specialty and Care Services pre-tax earnings surged 22% to $1.1B on faster adoption of specialty generics and biosimilars exceeding 80% penetration.
  • Pharmacy Benefit Services earnings declined year-over-year; GLP-1 growth moderating and Q2 specialty drug benefits not expected to repeat at same levels.
  • Signature rebate-free pharmacy model set for broader 2028 launch with 4% margin target; company exiting ACA exchange business to redeploy resources.
Last Updated: 07/30/2026, 09:58 PM
Read Full Transcript

FAQ

What Is Cigna's Earnings Per Share (TTM)?

The Cigna EPS (TTM) is 24.18.

When Is The Next Cigna Earnings Date?

Cigna will release its next earnings report on Oct 29, 2026.

What Is Cigna’s Revenue Forecasts For Upcoming Quarters?

Cigna’s revenue forecast is 72.63B.

How Did Cigna React to the Company's Latest Earnings Report?

Cigna reported a +2.5% EPS surprise and a +2.17% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -5.88%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.